Mateon Therapeutics Inc. buy klostergang
Start price
03.06.15
/
50%
€1.36
Target price
07.12.15
€1.70
Performance (%)
-39.82%
End price
07.12.15
€0.82
Summary
This prediction ended on 07.12.15 with a price of €0.82. The BUY prediction by klostergang for Mateon Therapeutics Inc. performed very badly with a performance of -39.82%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Mateon Therapeutics Inc. | - | - | - | - |
| iShares Core DAX® | -0.383% | 1.093% | 11.642% | 60.422% |
| iShares Nasdaq 100 | -0.411% | -1.973% | 7.273% | 87.823% |
| iShares Nikkei 225® | 1.838% | 10.261% | 31.381% | 66.929% |
| iShares S&P 500 | -0.712% | 0.445% | 4.295% | 60.457% |
Comments by klostergang for this prediction
In the thread Mateon Therapeutics Inc. diskutieren
Die FDA billigt PFS als primären Endpunkt der Phase-3-Studie :
http://seekingalpha.com/article/3228966-there-is-significant-upside-ahead-for-oxigene
(Vom Mitglied beendet)